Verona Pharma PLC (NAS:VRNA)

$ 30.01 -0.16 (-0.53%) Market Cap: 2.44 Bil Enterprise Value: 2.17 Bil PE Ratio: 0 PB Ratio: 14.42 GF Score: 29/100

Full Year 2023 Verona Pharma PLC Earnings Call Transcript
Feb 29, 2024

$17.22 (-0.23%)

Earnings
Verona Pharma PLC at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Verona Pharma PLC Earnings Call Transcript
Nov 02, 2023

$14.94 (+4.62%)

Earnings
Verona Pharma PLC Investor Launch Update Transcript
Oct 18, 2023
Verona Pharma PLC at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Q2 2023 Verona Pharma PLC Earnings Call Transcript
Aug 03, 2023

$20.04 (-2.88%)

Earnings
Verona Pharma PLC at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Verona Pharma PLC To Discuss The Phase 3 ENHANCE Data Presented At ATS 2023 Transcript
May 23, 2023
Q1 2023 Verona Pharma PLC Earnings Call Transcript
May 09, 2023

$22.47 (+2.74%)

Earnings
Full Year 2022 Verona Pharma PLC Earnings Call Transcript
Mar 07, 2023

$20.09 (-10.51%)

Earnings
Verona Pharma PLC Corporate Call Transcript
Dec 20, 2022
Q3 2022 Verona Pharma PLC Earnings Call Transcript
Nov 09, 2022

$12.35 (-4.49%)

Earnings
Q2 2022 Verona Pharma PLC Earnings Call Transcript
Aug 09, 2022

$10.03 (+44.32%)

Earnings
Verona Pharma PLC KOL event for analysts and investors Call Transcript
Jun 16, 2022
Q1 2022 Verona Pharma PLC Earnings Call Transcript
May 03, 2022

$4.06 (+4.10%)

Earnings
Q4 2021 Verona Pharma PLC Earnings Call Transcript
Mar 03, 2022

$5.58 (+1.27%)

Earnings
Q3 2021 Verona Pharma PLC Earnings Call Transcript
Nov 09, 2021

$5.17

Earnings
Q2 2021 Verona Pharma PLC Earnings Call Transcript
Aug 05, 2021

$6.25 (+4.69%)

Earnings
Q1 2021 Verona Pharma PLC Earnings Call Transcript
Apr 29, 2021

$6.8 (-5.56%)

Earnings
Verona Pharma PLC Annual Shareholders Meeting Transcript
Apr 27, 2021
Q4 2020 Verona Pharma PLC Earnings Call Transcript
Feb 25, 2021

$9.3 (+1.75%)

Earnings
Q3 2020 Verona Pharma PLC Earnings Call Transcript
Oct 29, 2020

$5.77 (-0.69%)

Earnings
Q2 2020 Verona Pharma PLC Earnings Call Transcript
Aug 14, 2020

$8.25 (+14.90%)

Earnings
Verona Pharma plc - Shareholder/Analyst Call Transcript
Jun 01, 2020
Q1 2020 Verona Pharma PLC Earnings Call Transcript
Apr 30, 2020

$4.24 (-28.26%)

Earnings
Q4 2019 Verona Pharma PLC Earnings Call Transcript
Feb 27, 2020

$6.23 (-7.57%)

Earnings
Verona Pharma plc - Special Call Transcript
Jan 13, 2020
Nine Months 2019 Verona Pharma PLC Earnings Call Transcript
Nov 05, 2019

$4.48 (-0.88%)

Earnings
Half Year 2019 Verona Pharma PLC Earnings Call Transcript
Aug 06, 2019

$4.23 (+2.42%)

Earnings
Verona Pharma PLC Investor & Analyst R&D Forum Transcript
May 08, 2019
Q1 2019 Verona Pharma PLC Earnings Call Transcript
May 07, 2019

$6.63 (+5.24%)

Earnings
Full Year 2018 Verona Pharma PLC Earnings Call Transcript
Feb 26, 2019

$5.52 (-4.66%)

Earnings

Verona Pharma PLC at Canaccord Genuity Growth Conference Transcript

Aug 09, 2023 / 04:00PM GMT

Release Date Price: $18.78 (+2.90%)

Transcript 10-Q8-K

Edward Nash

Canaccord Genuity Group Inc. - Analyst

Hi. Good afternoon, everyone. My name is Edward Nash, Senior Biotechnology Analyst on the biotech team here at Canaccord Genuity, appreciate everyone joining us. With us today from Verona Pharma, we have Chris Martin, who is the Senior Vice President of Commercial; and Tara Rheault, who is the Senior Vice President of R&D. Welcome to you both.

Chris Martin

Verona Pharma plc - SVP of Commercial

Thank you, Edward.

Tara Rheault

Verona Pharma plc - SVP of Research and Development

Thank you.

Edward Nash

Canaccord Genuity Group Inc. - Analyst

Just as I said with my previous company we had here, you guys are in the stage where I always like to see where the companies I follow for a while. You've now filed your NDA, which is being reviewed. So getting closer and closer to potential commercial. So you guys are the ideal people to be having on our panel today.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.